AMENDMENT TO THE CLAIMS

- 1. (Currently Amended) A method for treating a patient to reduce proliferation of and/or kill target cells that express an antigen, comprising
 - (a) administering one or more agents that cause apoptosis of the target cells; and
 - (b) administering an antibody immunoreactive with said antigen, and wherein said antibody is cytotoxic to said target cells.
- 2. (Original) The method of claim 1, wherein the target cells are transformed cells.
- 3. (Original) The method of claim 2, wherein the transformed cells are tumor cells.
- 4. (Original) The method of claim 1, wherein the treatment reduces the number of target cells in the patient.
- 5. (Original) The method of claim 1, wherein the agent that causes apoptosis and the antibody are administered to the patient conjointly.
- 6. (Original) The method of claim 1, wherein the antibody is administered to the patient after the agent that causes apoptosis.
- 7. (**Original**) The method of claim 1, wherein the antibody is administered to the patient prior to the agent that causes apoptosis.
- 8. (Original) The method of claim 1, wherein the one or more agents that cause apoptosis of the target cells is a chemotherapeutic agent.
- 9. (**Original**) The method of claim 1, wherein the antibody is a xenotypic monoclonal antibody.
- 10. (Original) The method of claim 9, wherein said xenotypic monoclonal antibody is selected from the group consisting of Alt-1, Alt-2, Alt-3, Alt-4, and Alt-5.
- 11. (Original) The method of claim 1, wherein the one or more agents that cause apoptosis and the antibody elicit an effective B and/or T cell response when administered to the patient.
- 12. (Original) The method of claim 11, wherein the effective T cell response is selected from the group consisting of a T helper response; a CTL response; and a T helper response and a CTL response.
- 13. (Original) The method of claim 1, wherein the patient is a human.

14-35. (Canceled)